Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives - Benzinga

This article reports on the strategic partnership between Certara and Silo Pharma with NVIDIA in AI agent development, highlighting the growing convergence between semiconductor and pharmaceutical ind... Read original →

NVIDIA’s AI Agent collaboration with Certara and Silo Pharma isn’t just about accelerating drug discovery—it’s a strategic wedge driving semiconductor tech deep into life sciences. The 3nm node and EUV lithography, primarily manufactured by TSMC (Taiwan, China), now underpin not only AI chip performance but also the computational backbone of modern pharmacology. This shift forces EDA vendors, HBM suppliers, and advanced packaging firms to adapt architectures to biomedical data patterns. Geopolitically, reliance on TSMC’s irreplaceable 3nm capacity exposes pharma firms to export control volatility, inflating supply chain insurance costs. Competitors like AMD and Intel may counter with open-standard platforms tailored for regulated healthcare environments. Within 18 months, AI Agents will expand beyond target identification into real-world evidence generation, compelling CROs to overhaul service models. Semiconductor players that fail to embed into vertical workflows—not just sell silicon—will face rapid commoditization.